The pharmaceutical lobby is showing its hand in the leadup to the 2018 midterm elections.
The New York Times reported that Big Pharma’s biggest fear is that Donald Trump will team up with Democrats to throttle drug prices.
“As the midterm elections approach, a feeling of foreboding has settled over the pharmaceutical industry,” John E. McManus, a GOP healthcare lobbyist who works with major drug companies, told the Times.
“Combine the rising blue wave — the Democrat fixation on pharmaceutical pricing — with President Trump’s populist focus on getting credit for cutting patients’ drug costs,” McManus added, “and the industry could be confronting a perfect storm in 2019.”
The report noted that if Democrats gain a majority in the House of Representatives, the Health Subcommittee on the powerful Ways and Means Committee will be under the power of Rep. Lloyd Doggett (D-TX), “an unyielding critic of what he calls price gouging by pharmaceutical companies.”
Drug companies are reportedly counting on the Senate “to stop legislation they oppose,” the Times noted — but their comfortable relationship is soon to change.
With the loss of Finance Committee pharma defender Sen. Orrin Hatch (R-UT) and his likely succession by the more-populist Chuck Grassley (R-IA) — a supporter of importing drugs from Canada — the industry may not have enjoy the control they had in the upper chamber.